Mathematical Modeling of the Acute Inflammatory Response Following Injury
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this research study is to gather clinical and biologic information from severely injured patients to better understand and characterize the host response to injury and inflammation across several domains. This information may improve outcome prediction, improve clinical treatment of injured patients, and permit the construction of non-biologic computerized models of illness that can be utilized to represent the host response in future research efforts. This study is designed as the calibration of a mathematical model of this response with predictive capabilities.
The central hypothesis governing this study is that adaptive immune elements are crucial to determining the outcome of complex inflammatory scenarios. We propose to test these hypotheses in the following interrelated Specific Aims:
Specific Aim 1: To develop a robust mathematical model describing trauma/hemorrhage-induced inflammation in humans, its pathologic consequences, and possible therapies.
Specific Aim 2: To translate the mathematical model to humans and create software aimed at individualized clinical decision-making.
Specific Aim 3: To determine the prevalence of an IL-1 receptor-associated kinase (IRAK-1) variant haplotype located on the X-chromosome in an injured population, and to characterize differences in the pro-inflammatory response across gender, relative to the IRAK-1 haplotype.
Specific Aim 4: To determine if increased arginase activity previously observed in isolated peripheral blood mononuclear cells of trauma patients is a consequence of the presence of contaminating activated granulocytes or a particular subset of an arginase positive monocyte subset.
| Condition |
|---|
|
Trauma Critical Illness |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Host Response to Injury |
For trauma injury cohort: The maximum blood volume collected over the 28 day period, if all samples are obtained, is approximately 90 cc. All standard precautions will be undertaken to assure minimal risk.
Blood samples will be obtained for genetic analysis of inflammatory gene polymorphisms. We will collect whole blood, serum and white cells.
| Estimated Enrollment: | 520 |
| Study Start Date: | February 2003 |
| Estimated Study Completion Date: | July 2014 |
| Estimated Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Traumatic injury
ICU Patients with blunt or penetrating injury
|
|
2
Healthy volunteers
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Subjects to be recruited will consist of trauma patients and healthy volunteers:
Trauma patient cohort inclusion criteria:
- Present for treatment of their acute, blunt or penetrating injuries to the University of Pittsburgh Medical Center within 6 hours of injury
- Age greater than or equal to 18 years
- Intact cervical spinal cord
- Are admitted to the Intensive Care Unit
Trauma patient cohort exclusion criteria:
- Anticipated survival < 24 hrs
- Anticipated survival < 28 days due to pre-existing condition
- Traumatic Brain injury (GCS ≤8 after ICU admission) AND brain CT abnormality within 12 hr of injury
- Inability to obtain consent from the subject or their legally authorized representative.
- Pre-existing immunosuppression
- Transplant recipient
- Chronic high doses of steroids (>20 mg prednisone equivalents/day)
- Significant likelihood of high dose steroids (e.g. spinal cord injury)
- Oncolytic drug(s) therapy within the past 14 days
- Known HIV positive status and CD4 count < 200 cells/mm3
- Admission to the ICU primary for substance withdrawal.
- Inability to obtain 1st blood sample within 24 hours of injury.
Healthy volunteer cohort inclusion:
- Age greater than or equal to 18 years
- Weight > 110 pounds
- no recent illness or infection in the last two weeks
- no recent hospitalization or trauma in the last month
Healthy volunteer cohort exclusion:
- wt < 110 lbs
- infection or illness in the last two weeks
- Hospitalization or trauma in the last month
Contacts and Locations| Contact: Stacy D Stull, MS | 412-692-4338 | stullsd@upmc.edu |
| United States, Pennsylvania | |
| University of Pittsburgh Medical Center | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Principal Investigator: Juan B Ochoa, MD., FACS | |
| Principal Investigator: | Juan B Ochoa, MD., FACS. | UPMC Department of Surgery/Critical Care Medicine |
More Information
No publications provided
| Responsible Party: | Yoram Yodovotz, Ph.D., University of Pittsburgh |
| ClinicalTrials.gov Identifier: | NCT00250523 History of Changes |
| Other Study ID Numbers: | PRO 0801232, P50-GM-53789 |
| Study First Received: | November 7, 2005 |
| Last Updated: | July 22, 2010 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institute of General Medical Sciences (NIGMS):
|
trauma critical illness injury |
Additional relevant MeSH terms:
|
Critical Illness Disease Attributes Pathologic Processes |
ClinicalTrials.gov processed this record on May 16, 2013